AVDL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVDL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Avadel Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2023 was 0.00.
The historical rank and industry rank for Avadel Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Avadel Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Avadel Pharmaceuticals is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Avadel Pharmaceuticals (NAS:AVDL) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Avadel Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas S Mchugh | officer: Chief Financial Officer | 2280 SCHUETZ ROAD, ST. LOUIS MO 63146 |
Mark Anthony Mccamish | director | C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
Geoffrey Michael Glass | director | 4721 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
Greg J Divis | director, officer: Chief Executive Officer | 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
Richard J Kim | officer: Chief Commercial Officer | 16 FAIRWAY DRIVE, WEST WINDSOR NJ 08550 |
Eric J Ende | director | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Linda Palczuk | director | 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046 |
Peter Thornton | director | TECHNOPATH LIFE SCIENCES PARK, FORT HENRY, BALLINA, CO. TIPPERARY L2 V94 FF1P |
Douglas J Williamson | officer: Chief Medical Officer | AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390 |
Sandra L Hatten | officer: See Remarks | 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
Jason Vaughn | officer: Sr. VP, Technical Operations | 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
Jordan Dubow | officer: Chief Medical Officer | 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
Michael F Kanan | officer: See Remarks | 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
David P Gusky | officer: See Remarks | 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
Michael S Anderson | director, officer: Chief Executive Officer | 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
From GuruFocus
By Marketwired • 10-05-2023
By Marketwired • 08-09-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 08-31-2023
By sperokesalga sperokesalga • 03-30-2023
By sperokesalga sperokesalga • 03-29-2023
By GuruFocus Research • 08-11-2023
By Marketwired • 08-03-2023
By Marketwired • 08-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.